Browse BCR

Summary
SymbolBCR
Namebreakpoint cluster region
Aliases D22S662; CML; PHL; ALL; D22S11; BCR1; ALL1; BCR/FGFR1 chimera protein; FGFR1/BCR chimera protein; renal carc ......
Chromosomal Location22q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell junction, synapse, postsynaptic cell membrane, postsynaptic density
Domain PF09036 Bcr-Abl oncoprotein oligomerisation domain
PF00168 C2 domain
PF00620 RhoGAP domain
PF00621 RhoGEF domain
Function

GTPase-activating protein for RAC1 and CDC42. Promotes the exchange of RAC or CDC42-bound GDP by GTP, thereby activating them. Displays serine/threonine kinase activity.

> Gene Ontology
 
Biological Process GO:0001974 blood vessel remodeling
GO:0002237 response to molecule of bacterial origin
GO:0002263 cell activation involved in immune response
GO:0002274 myeloid leukocyte activation
GO:0002275 myeloid cell activation involved in immune response
GO:0002283 neutrophil activation involved in immune response
GO:0002366 leukocyte activation involved in immune response
GO:0002443 leukocyte mediated immunity
GO:0002444 myeloid leukocyte mediated immunity
GO:0002446 neutrophil mediated immunity
GO:0002683 negative regulation of immune system process
GO:0002685 regulation of leukocyte migration
GO:0002686 negative regulation of leukocyte migration
GO:0002691 regulation of cellular extravasation
GO:0002692 negative regulation of cellular extravasation
GO:0002694 regulation of leukocyte activation
GO:0002695 negative regulation of leukocyte activation
GO:0002697 regulation of immune effector process
GO:0002698 negative regulation of immune effector process
GO:0002703 regulation of leukocyte mediated immunity
GO:0002704 negative regulation of leukocyte mediated immunity
GO:0002886 regulation of myeloid leukocyte mediated immunity
GO:0002887 negative regulation of myeloid leukocyte mediated immunity
GO:0003013 circulatory system process
GO:0003018 vascular process in circulatory system
GO:0006887 exocytosis
GO:0006909 phagocytosis
GO:0007265 Ras protein signal transduction
GO:0007266 Rho protein signal transduction
GO:0007423 sensory organ development
GO:0008015 blood circulation
GO:0017157 regulation of exocytosis
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0030100 regulation of endocytosis
GO:0030336 negative regulation of cell migration
GO:0031348 negative regulation of defense response
GO:0032102 negative regulation of response to external stimulus
GO:0032496 response to lipopolysaccharide
GO:0034103 regulation of tissue remodeling
GO:0034104 negative regulation of tissue remodeling
GO:0035023 regulation of Rho protein signal transduction
GO:0036230 granulocyte activation
GO:0040013 negative regulation of locomotion
GO:0042119 neutrophil activation
GO:0042471 ear morphogenesis
GO:0042472 inner ear morphogenesis
GO:0043114 regulation of vascular permeability
GO:0043299 leukocyte degranulation
GO:0043300 regulation of leukocyte degranulation
GO:0043301 negative regulation of leukocyte degranulation
GO:0043312 neutrophil degranulation
GO:0043313 regulation of neutrophil degranulation
GO:0043314 negative regulation of neutrophil degranulation
GO:0043583 ear development
GO:0045055 regulated exocytosis
GO:0045123 cellular extravasation
GO:0045807 positive regulation of endocytosis
GO:0045920 negative regulation of exocytosis
GO:0046578 regulation of Ras protein signal transduction
GO:0046777 protein autophosphorylation
GO:0048008 platelet-derived growth factor receptor signaling pathway
GO:0048562 embryonic organ morphogenesis
GO:0048568 embryonic organ development
GO:0048771 tissue remodeling
GO:0048839 inner ear development
GO:0050727 regulation of inflammatory response
GO:0050728 negative regulation of inflammatory response
GO:0050764 regulation of phagocytosis
GO:0050766 positive regulation of phagocytosis
GO:0050777 negative regulation of immune response
GO:0050865 regulation of cell activation
GO:0050866 negative regulation of cell activation
GO:0050885 neuromuscular process controlling balance
GO:0050900 leukocyte migration
GO:0050905 neuromuscular process
GO:0051048 negative regulation of secretion
GO:0051051 negative regulation of transport
GO:0051056 regulation of small GTPase mediated signal transduction
GO:0051271 negative regulation of cellular component movement
GO:0060312 regulation of blood vessel remodeling
GO:0060313 negative regulation of blood vessel remodeling
GO:0060627 regulation of vesicle-mediated transport
GO:0090596 sensory organ morphogenesis
GO:1902563 regulation of neutrophil activation
GO:1902564 negative regulation of neutrophil activation
GO:1903305 regulation of regulated secretory pathway
GO:1903306 negative regulation of regulated secretory pathway
GO:1903531 negative regulation of secretion by cell
GO:2000146 negative regulation of cell motility
Molecular Function GO:0004674 protein serine/threonine kinase activity
GO:0004713 protein tyrosine kinase activity
GO:0005085 guanyl-nucleotide exchange factor activity
GO:0005088 Ras guanyl-nucleotide exchange factor activity
GO:0005089 Rho guanyl-nucleotide exchange factor activity
GO:0005096 GTPase activator activity
GO:0008047 enzyme activator activity
GO:0030695 GTPase regulator activity
GO:0060589 nucleoside-triphosphatase regulator activity
Cellular Component GO:0014069 postsynaptic density
GO:0045211 postsynaptic membrane
GO:0060076 excitatory synapse
GO:0097060 synaptic membrane
GO:0098794 postsynapse
GO:0099572 postsynaptic specialization
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-1839124: FGFR1 mutant receptor activation
R-HSA-194840: Rho GTPase cycle
R-HSA-162582: Signal Transduction
R-HSA-1226099: Signaling by FGFR in disease
R-HSA-5655302: Signaling by FGFR1 in disease
R-HSA-194315: Signaling by Rho GTPases
R-HSA-1839117: Signaling by cytosolic FGFR1 fusion mutants
Summary
SymbolBCR
Namebreakpoint cluster region
Aliases D22S662; CML; PHL; ALL; D22S11; BCR1; ALL1; BCR/FGFR1 chimera protein; FGFR1/BCR chimera protein; renal carc ......
Chromosomal Location22q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between BCR and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between BCR and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
10688838Chronic myelogenous leukemia, BRC-ABL1 positivePromote immunityVaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses.
21540460Chronic Lymphocytic LeukemiaPromote immunity (T cell function)Donor-derived mature dendritic cells generated in vitro from CD14(+) monocytes were loaded with human leukocyte Ag-restricted peptides derived from PR1, WT1, and/or B-cell receptor-ABL and used to repetitively stimulate donor CD8(+) T cells in the presence of IL-2 and IL-7.
Summary
SymbolBCR
Namebreakpoint cluster region
Aliases D22S662; CML; PHL; ALL; D22S11; BCR1; ALL1; BCR/FGFR1 chimera protein; FGFR1/BCR chimera protein; renal carc ......
Chromosomal Location22q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of BCR in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolBCR
Namebreakpoint cluster region
Aliases D22S662; CML; PHL; ALL; D22S11; BCR1; ALL1; BCR/FGFR1 chimera protein; FGFR1/BCR chimera protein; renal carc ......
Chromosomal Location22q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of BCR in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1560.665
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.7310.62
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.260.824
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0180.952
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0520.983
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0210.994
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3380.373
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1810.903
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.5190.753
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0890.944
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.1050.955
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1070.14
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of BCR in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141714.35.98.40.576
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103200201
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.15.55.60.384
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.16.84.30.673
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.811.8-70.577
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.718.2-10.50.576
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.93.74.20.636
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.6013.60.279
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolBCR
Namebreakpoint cluster region
Aliases D22S662; CML; PHL; ALL; D22S11; BCR1; ALL1; BCR/FGFR1 chimera protein; FGFR1/BCR chimera protein; renal carc ......
Chromosomal Location22q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of BCR. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolBCR
Namebreakpoint cluster region
Aliases D22S662; CML; PHL; ALL; D22S11; BCR1; ALL1; BCR/FGFR1 chimera protein; FGFR1/BCR chimera protein; renal carc ......
Chromosomal Location22q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of BCR. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by BCR.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolBCR
Namebreakpoint cluster region
Aliases D22S662; CML; PHL; ALL; D22S11; BCR1; ALL1; BCR/FGFR1 chimera protein; FGFR1/BCR chimera protein; renal carc ......
Chromosomal Location22q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of BCR. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolBCR
Namebreakpoint cluster region
Aliases D22S662; CML; PHL; ALL; D22S11; BCR1; ALL1; BCR/FGFR1 chimera protein; FGFR1/BCR chimera protein; renal carc ......
Chromosomal Location22q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of BCR expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolBCR
Namebreakpoint cluster region
Aliases D22S662; CML; PHL; ALL; D22S11; BCR1; ALL1; BCR/FGFR1 chimera protein; FGFR1/BCR chimera protein; renal carc ......
Chromosomal Location22q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between BCR and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolBCR
Namebreakpoint cluster region
Aliases D22S662; CML; PHL; ALL; D22S11; BCR1; ALL1; BCR/FGFR1 chimera protein; FGFR1/BCR chimera protein; renal carc ......
Chromosomal Location22q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting BCR collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting BCR.
ID Name Drug Type Targets #Targets
DB01254DasatinibSmall MoleculeABL1, ABL2, BCR, BTK, CSK, EPHA2, EPHA5, EPHB4, FGR, FRK, FYN, HSP ......22
DB06616BosutinibSmall MoleculeABL1, BCR, CAMK2G, CDK2, HCK, LYN, MAP2K1, MAP2K2, MAP3K2, SRC10
DB08901PonatinibSmall MoleculeABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, P ......15